Titlebook: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics; Michelle A. Rudek,Cindy H. Chau,Howard L. McLeod Book 2014Latest edition Spr

malcontented

書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)學(xué)科排名




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開度




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次學(xué)科排名




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用學(xué)科排名




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋




書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋學(xué)科排名

Directed

browbeat

Phase 0 Trials in Oncology,gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical

Inflamed

Traumatic-Grief

Protein Binding,es in which monitoring of unbound concentrations might be useful: (1) agents demonstrating protein concentration-dependent binding, (2) agents that bind irreversible or near covalently, (3) when formulation excipients modulate unbound drug levels, and (4) metabolically interconversible agents. While

fertilizer

Handbook of Anticancer Pharmacokinetics and Pharmacodynamics

Adherent

The Vegetation and Physiography of Sumatraal and each has a role for specific drugs. However, no one method is a practical dose calculation strategy for many or all drugs. Neither body size nor fixed dosing alone can be used for currently available drugs. Conclusion: Dosing strategies for anticancer drugs should be individualized according

大溝

https://doi.org/10.1007/978-94-015-8066-3gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical

Goblet-Cells

HARP